Regulating Liver Tumors via Selective Hepatic Vagotomy
Author Information
Author(s): Kylynda C. Bauer, Shadin Ghabra, Chi Ma, Lee Chedester, Tim F. Greten, Fernando Albericio
Primary Institution: National Cancer Institute (NCI), National Institutes of Health (NIH)
Hypothesis
Can selective hepatic vagotomy influence liver cancer progression and treatment outcomes?
Conclusion
The study provides a detailed methodology for performing selective hepatic vagotomy in mice, which may help in understanding the neuroimmune interactions in liver cancer.
Supporting Evidence
- The liver is a primary site for cancer metastasis, with over one quarter of all metastatic cancer developing within it.
- Vagal nerves have been linked to metabolic and inflammatory responses in the liver.
- Previous studies indicated that vagotomy can reduce liver tumor burden.
Takeaway
This study shows how a specific surgery on nerves in the liver can help scientists learn more about liver cancer and how to treat it.
Methodology
The study describes a protocol for performing selective hepatic vagotomy in mice with liver tumors, using an established liver metastatic model.
Limitations
The methodology may not be applicable to all cancer models and requires further validation in different contexts.
Participant Demographics
The study used BALB/cAnNCrl mice, specifically 8–12 weeks old.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website